Drug Profile

N 17350

Alternative Names: N-17350; NEU-001 - Onchilles Pharma

Latest Information Update: 20 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Onchilles Pharma
Class Antineoplastics
Mechanism of Action Apoptosis stimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

07 Nov 2025 Onchilles Pharma expects an IND clearance for Solid tumours in USA, by June 2026
07 Nov 2025 Onchilles Pharma announces intention to initiate a first-in-human proof-of-concept clinical trial in Solid tumours (Monotherapy) in Australia (Intratumoural, Injection), in early 2026
07 Nov 2025 Pharmacodynamics and adverse events data from preclinical studies in Solid tumours released by Onchilles Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com